Pfizer's (NYSE: PFE) management team is confident in its 2025 opportunities. Where to invest $1,000 right now? Our analyst ...

Here is why Pfizer can't seem to get off the mat and whether it's worth buying the dip on today. I won't rehash Pfizer's pandemic journey too much. The company developed and sold a vaccine (Comirnaty) ...

Pfizer (PFE) closed at $27.41 in the latest ... changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

Pfizer (NYSE: PFE) is a great example, with its shares down around 57% below the previous high. When a stock plunges as much ...

Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...

Tuesday was a relatively uneventful news day for Pfizer ... pandemic. The market is likely to start getting more impatient with the company soon. The Motley Fool Stock Advisor analyst team ...

The remarkable improvement was driven by the strong performance of Pfizer's core portfolio ... and then choose between a market order or a limit order to buy the stock. To sell shares of Pfizer ...

In the latest market close, Pfizer ... company's business performance and profit potential. Based on our research, we believe these estimate revisions are directly related to near-team stock ...